Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Nastoupil

Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Related publications

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone Prior to Combination With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Lenalidomide and Obinutuzumab With Chop for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I/Ii Results

Hematological Oncology

English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

English

Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-Line Chemotherapy in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma

English

Correlation of Pretreatment 18f-FDG Uptake With Clinicopathological Factors and Prognosis in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Nuclear Medicine Communications

English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Population Pharmacokinetics of Rituximab in Patients With Diffuse Large B-Cell Lymphoma and Association With Clinical Outcome

British Journal of Clinical Pharmacology

Pharmacology

2017

English

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Journal of Clinical Oncology

English

The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Nastoupil

Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Related publications

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone Prior to Combination With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Lenalidomide and Obinutuzumab With Chop for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I/Ii Results

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-Line Chemotherapy in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma

Correlation of Pretreatment 18f-FDG Uptake With Clinicopathological Factors and Prognosis in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Population Pharmacokinetics of Rituximab in Patients With Diffuse Large B-Cell Lymphoma and Association With Clinical Outcome

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era